Application Detail
Description of Medical Service
The Stockholm3 is a multiparametric blood-based test that uses protein and genetic analysis combined with clinical data and an algorithm to estimate the risk of having clinically significant prostate cancer. This test is intended for men with no previous prostate cancer diagnosis, aged 45-74 years and have an elevated prostate specific antigen (PSA) level, who want to assess the risk of prostate cancer.Description of Medical Condition
Prostate cancer develops when abnormal cells in the prostate gland grow in an uncontrolled way, forming a malignant tumour. Localised prostate cancer is where the cancer cells do not appear to have spread beyond the prostate, alternatively advanced or metastatic prostate cancer is where the cancer has spread outside the prostate. Prostate cancer is estimated to be the most commonly diagnosed cancer for males and for Australia overall, with an estimated 25,500 cases diagnosed in 2023.Reason for Application
New MBS itemMedical Service Type
Investigative technologyPrevious Application Number/s
Not ApplicableAssociated Documentation
Application Summary and PICO Set
Application Summary (PDF 167 KB)Application Summary (Word 24 KB)
Application PICO Set (PDF 527 KB)
Application PICO Set (Word 122 KB)
Consultation Survey
Consultation SurveyPASC Consultation
PASC consultation closes Friday 12 July 2024. Any consultation received after this date will automatically be included in the MSAC consultation for this application.
MSAC Consultation
MSAC consultation TBA – please subscribe to the MSAC email bulletin to be notified when this application is scheduled for MSAC consideration. The bulletin will also advise the closing date for consultation input.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation proves please refer to MSAC Consultation Process